**Exhibit 10.33**

**AMENDMENT TO SUBLICENSE AGREEMENT**

            This Amendment to Sublicense  Agreement (this "**Amendment**") is entered into on this 28th day of February, 2002 ("**Effective Date**"), by and  between Procept, Inc. (formerly Pacific Pharmaceuticals, Ins.), a Delaware corporation with offices at 369 Lexington Avenue, 10th  Floor, New York, New York 10017 ("**Procept**"), and AOI Pharmaceuticals, Inc., a subsidiary of Access Oncology, Inc., a Delaware  corporation with offices at 750 Lexington Avenue, 26th Floor, New York, New York 10022 ("**AOIP**") (Procept and  AOIP sometimes collectively referred to as "**Parties**").

            **WHEREAS**, Proceptentered into a license agreement (the "**License Agreement**") on or about March 17, 1998 with The Penn State ResearchFoundation ("**Foundation**"), pursuant to which Procept received an exclusive worldwide license to certain Patent Rights(as defined therein) and Know-how (as defined therein);

            **WHEREAS**, Procepthas sub-licensed certain of its interests, rights and obligations under the License Agreement to AOIP pursuant to a sublicenseagreement entered into by and between Procept and AOIP on or about October 13, 2000 (such sublicense agreement, the"**Sublicense Agreement**");

            **WHEREAS**,Foundation and the United States Public Health Service have agreed to enter into an interinstitutional agreement (the"**Interinstitutional Agreement**"), a copy of which is attached hereto as Exhibit A, pursuant to which Foundation shallexclusively license its rights under the License Agreement to PHS, such Interinstitutional Agreement to become effective uponexecution of the Revised License Agreement (as defined below);

            **WHEREAS**, Proceptand PHS have agreed to enter into a revised license agreement, a copy of which is attached hereto as Exhibit B, regarding thePatent Rights (such revised license agreement, the "**Revised License Agreement**"), which Revised License Agreementshall supersede and terminate the terms and conditions of the License Agreement;

            **WHEREAS**, as acondition to executing the Revised License Agreement, PHS has requested that Procept amend the Sublicense Agreement to securecertain obligations from AOIP;

            **WHEREAS**, Proceptand AOIP wish to facilitate the development and commercialization of the Licensed Products) and Licensed Processes) (as such termsare defined in the Revised License Agreement);

            **NOW, THEREFORE**,in consideration of the foregoing premises and the mutual covenants herein contained, and for other good and valuableconsideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree to the following:

----

-  AOIP shall be bound by the terms ofSection 4.02 of the Revised License Agreement. 
-  AOTP shall not sublicense its rightsunder the Sublicense Agreement without the consent of PHS, which consent shall not be unreasonably withheld, and without reasonablenotice to Procept. 
-  This Amendmentwill be governed by and construed in accordance with the laws of the State ofNew York without regard to its conflict of law rules. 
-  This Amendmentmay be signed in one or more counterparts, each of which is to be considered anoriginal, and taken together as one and the same document. 

            **IN WITNESSWHEREOF**, the Parties acknowledge by the signatures below of their authorized representatives that they have read this Amendmentand understand and agree to be bound by its terms and conditions.

 

| PROCEPT, INC.      369 Lexington Avenue      10th Floor      New York, NY 10017                                                                                                                                                                                                                                       | AOI PHARMACEUTICALS, INC.      An Access Oncology Company      750 Lexington Avenue      26th FloorNew York, NY 10022                                                                                                                                                                                                                                          |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                |
|                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                |
| By:  /s/  Salvatore A. Bucci                         Name: Salvatore A. Bucci      Title:   President and Chief Executive Officer | By:  /s/  I. Craig Henderson                                Name:  I. Craig Henderson            Title:   Chief Executive Officer  |
|                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                |